Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
BioNTech, Bristol Myers' Pumitamig Shows 36.7% Response Rate In Phase 2 NSCLC Trial
BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?
Berenberg Bank Sticks to Their Hold Rating for Qiagen (QGEN)
Sterling Capital Management LLC Acquires 88,344 Shares of Gilead Sciences, Inc. $GILD - Stock Observer
7,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A. - Daily Political
Gilead Sciences, Inc. $GILD Stock Holdings Raised by Royal Fund Management LLC - Zolmax
Gilead Sciences, Inc. $GILD Stock Bought by Royal Fund Management LLC - Markets Daily
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
BioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With Gilead
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Morningstar
BioNTech (BNTX) Heads To ESMO 2026 With First ROSETTA Lung 107 Data
BNTX: Oncology Execution Matters Most, Cost Cuts Back The Path To Profits
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Trial Miss Might Change The Case For Investing In BioNTech Stock (BNTX)
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Assenagon Asset Management S.A.
BioNTech (NASDAQ:BNTX) Stock Gets Price Target Reduction from Canaccord Genuity Group - Markets Daily
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
BioNTech (BNTX), What Is Behind The Latest Attention?
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX) | Morningstar
Canaccord Genuity Group Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX) Stock Price Target Cut by Canaccord Genuity Group - Daily Political
BioNTech (BNTX) Is Down 7.0% After mRNA Cancer Trial Misses PFS Goal Has The Bull Case Changed?
Critical Analysis: MiMedx Group (NASDAQ:MDXG) vs. BioNTech (NASDAQ:BNTX) - Daily Political
BioNTech's mRNA Cancer Therapy Fails Key Trial Objective in Head and Neck Cancer, ETPharma
What Does BioNTech (BNTX) Trial Miss Mean For Its Oncology Pipeline?
Sivik Global Healthcare LLC Makes New $2.16 Million Investment in BioNTech SE Sponsored ADR $BNTX
BioNTech (NASDAQ:BNTX) Shares Down 5.5% - Here's What Happened
BioNTech mRNA cancer immunotherapy misses first objective in key study
BioNTech Shares Fall 5% as BNT113 Cancer Trial Misses Progression-Free Survival Endpoint
BioNTech stock falls after cancer trial misses key endpoint
BioNTech's BNT113 Misses Progression-Free Survival Endpoint In Phase 3 Head And Neck Cancer Trial
BioNTech Continues AHEAD-MERIT Trial Despite BNT113's PFS Endpoint Miss
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
BioNTech (NASDAQ:BNTX) Research Coverage Started at Argus - Stock Observer
BioNTech (NASDAQ:BNTX) CEO Sells $2,300,640.00 in Stock - Markets Daily
BioNTech (NASDAQ:BNTX) CEO Sells 27,000 Shares of Company Stock - Markets Daily
BioNTech (NASDAQ: BNTX) CEO sells all direct shares under trading plan - Stock Observer
Moderna stock jumps on planned national cancer vaccine effort
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
12,163 BioNTech SE Sponsored ADR $BNTX Shares Sold by Crocodile Capital Partners GmbH - Daily Political
Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $7,000,560.00 in Stock - Daily Political
BioNTech (NASDAQ:BNTX) Now Covered by Argus
BioNTech (NASDAQ:BNTX) Stock Picked Up by Analysts at Argus - Zolmax
Is BioNTech (BNTX) Undervalued On Pipeline Promise Despite Revenue Of €2,650.0 Million And Losses?
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Now Rated "Moderate Buy" by Wall Street Analysts - Daily Political
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 24,000 Shares of Stock
Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?
BNTX Maintained by Morgan Stanley -- Price Target Lowered to $11
BioNTech (NASDAQ: BNTX) CEO sells 93,000 shares under preplanned deal - Markets Daily
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 72,000 Shares
Moderna Is Up 545% in 2026: Take Profits Now, or Keep Buying?
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 72,000 Shares of Company Stock - Stock Observer
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Average Price Target of $126.00 According to Brokerages - Markets Daily
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Consensus Target Price of $126.00
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 17,000 Shares
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
BioNTech (NASDAQ:BNTX) CEO Sells $2,664,630.00 in Stock - Markets Daily
BioNTech (NASDAQ:BNTX) CEO Sells $3,347,980.00 in Stock - Stock Observer
BioNTech CEO sold shares under plan - Stock Observer
BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 32,000 Shares of Stock
BioNTech Closes Manufacturing Sites in Germany and Singapore Amidst Failed Sales, ETPharma
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 Shares
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 34,000 Shares
How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story
BioNTech News
CoreWeave Stock Forecast 2026–2030: Can CRWV Recover From the AI Debt Sell-Off?
Nebius Stock Price Prediction 2026–2030: Can AI Cloud Growth Justify the Cost?
Eli Lilly Stock Forecast 2026–2030: Can LLY Break Above $1,300 After Its 7% Five-Session Rally?
Is Oracle a Good Buy Right Now? Growth, Valuation and Long-Term Risks
Latest news
Show more
Microsoft Earnings Preview: Can Azure Growth Justify Rising AI Spending?
US Dollar Index Edges Lower Ahead of Fed Decision and Big Tech Earnings
Fed Rate Decision Preview: Will Kevin Warsh Hold Rates at 4% and Signal a December Hike?
Bitcoin Price Today Falls Below $80,000 as ETF Outflows and Liquidations Deepen the Sell-Off
Gold Price Forecast This Week: Can XAU/USD Reclaim $4,000 Before the Fed Decision?
